EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
S
Scott Goebel, MD
Primary Investigator
Enrolling By Invitation
1-30 years
All
Phase
2
20 participants needed
2 Locations
Overview
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured withhe Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children,dolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem
Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ.
Funding Source: FDA OOPD
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
-
Age: Between 1 Month - 30 Years
-
Gender: All
- Patients with Epstein-Barr virus infections post allogeneic HSCT, primary
immunodeficiencies or post solid organ transplant with:
- Increasing or persistent quantitative EBV RT-PCR DNA copies despite two weeks ofviral therapy and/or
- progressive clinical symptoms attributable to EBV, including biopsy proven colitis,ymphadenopathy, hepatomegaly, splenomegaly AND/OR
- Medical intolerance to anti-viral therapies including:
- intolerance to rituximab Consent: Written informed consent given (by patient or legalve) prior to any study-related procedures.
Updated on
15 May 2024.
Study ID: NYMC 581, PHO-NYMC-581EBV, 12864
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu